Desarda Tissue Technique vs Lichtenstein Technique for Primary Inguinal Hernia Repair
Launched by CONSORCI SANITARI DE L'ALT PENEDÈS I GARRAF · Oct 18, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different surgical techniques for fixing a common condition called an inguinal hernia, which occurs when tissue pushes through a weak spot in the abdominal muscles. The trial will compare the Desarda technique, which does not use a mesh, to the Lichtenstein technique, which does use a mesh. Researchers want to find out if one method leads to fewer complications after surgery than the other.
To be eligible for this study, participants must be diagnosed with a primary inguinal hernia and have a body mass index (BMI) below 31. They should also be able to give informed consent and need surgery either as an outpatient or with a planned hospital stay. However, certain patients, such as those with specific health conditions or previous surgeries that may complicate the procedure, will not be included. If you decide to participate, you can expect to undergo one of the two surgical techniques and be monitored for any complications following the surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with primary inguinal hernia.
- • Body mass index below 31
- • Indication for inguinal hernia repair via anterior approach, either as outpatient surgery (CMA) or elective admission.
- • Legal capacity to provide informed consent.
- Exclusion Criteria:
- • Patients with a weak, thin, or divided external oblique aponeurosis.
- * Participants diagnosed with any of the following conditions:
- • Ongoing oncological disease
- • Cirrhotic patients classified as Child B or higher
- • Women who have previously undergone a cesarean section
- • Cognitive or affective conditions that limit the ability to cooperate with the study procedures
About Consorci Sanitari De L'alt Penedès I Garraf
Consorci Sanitari de l'Alt Penedès i Garraf is a leading healthcare consortium located in Catalonia, Spain, dedicated to providing high-quality medical services and advancing clinical research. With a commitment to innovation and patient-centered care, the consortium integrates various health services, including hospitals and specialized care facilities, to enhance health outcomes in the Alt Penedès and Garraf regions. By fostering collaboration among healthcare professionals and engaging in clinical trials, the consortium aims to contribute to the development of new therapies and improve the overall healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sant Pere De Ribes, Barcelona, Spain
Patients applied
Trial Officials
Javier Errando, MD
Principal Investigator
CSAPG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported